Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 47Polycystic Ovary Syndrome 6Infertility 2Hyperandrogenism 2Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunction, Physiological 1Prostatic Intraepithelial Neoplasia 1Prostate Adenocarcinoma 1Primary Dysautonomias 1Overweight 1Ovarian Neoplasms 1Oligomenorrhea 1Neoplasm Metastasis 1Metabolic Syndrome 1Kidney Diseases 1Insulin Resistance 1Hypertension 1Hirsutism 1Castration-resistant Prostate Cancer 1Carcinoma, Ovarian Epithelial 1Anovulation 1Amenorrhea 1Adenocarcinoma 1

Interventions

Paclitaxel 326Carboplatin 318Bevacizumab 167Gemcitabine 106pembrolizumab 100liposomal doxorubicin 100Cyclophosphamide 94Topotecan 93Cisplatin 89olaparib 86niraparib 60Docetaxel 56Taxes 52Doxorubicin 50Drug Therapy 42fludarabine 39Filgrastim 39Nivolumab 37Etoposide 32Specimen Handling 31Magnetic Resonance Spectroscopy 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Albumin-Bound Paclitaxel 25durvalumab 24aldesleukin 24Hyperthermic Intraperitoneal Chemotherapy 24Oxaliplatin 23Biopsy 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Ovarian Neoplasms × Flutamide × Clear all
NCT00699907 2018-07-24

Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer

University of Arizona

Phase 2 Completed
127 enrolled 14 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡